Lifecore Biomedical (Lifecore Biomedical) Cash-to-Debt : 0.17 (As of May. 2023)

Lifecore Biomedical Cash-to-Debt Chart

Lifecore Biomedical Annual Data
	Trend	May14	May15	May16	May17	May18	May19	May20	May21	May22	May23
Cash-to-Debt		Get a 7-Day Free Trial					0.01	-	0.01	0.01	0.17

Lifecore Biomedical Quarterly Data
	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23
Cash-to-Debt	Get a 7-Day Free Trial															0.01	0.03	0.04	0.02	0.17

Competitive Comparison of Lifecore Biomedical's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lifecore Biomedical's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Cash-to-Debt falls into.

Lifecore Biomedical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Lifecore Biomedical's Cash to Debt Ratio for the fiscal year that ended in May. 2023 is calculated as:

Lifecore Biomedical's Cash to Debt Ratio for the quarter that ended in May. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical  (NAS:LFCR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Lifecore Biomedical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Lifecore Biomedical (Lifecore Biomedical) Business Description